Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices ― United States, 2023

What is already known about this topic?

Meningococcal disease is a life-threatening invasive infection caused by Neisseria meningitidis. The pentavalent meningococcal vaccine (MenACWY-TT/MenB-FHbp [Penbraya, Pfizer Inc.]) protects against N. meningitidis serogroups A, B, C, W, and Y and is licensed for use among persons aged 10–25 years.

What is added by this report?

On October 25, 2023, the Advisory Committee on Immunization Practices recommended that MenACWY-TT/MenB-FHbp may be administered to persons aged ≥10 years when both a quadrivalent meningococcal conjugate vaccine (MenACWY) and meningococcal B vaccine (MenB) are indicated at the same visit.

What are the implications for public health practice?

MenACWY-TT/MenB-FHbp is the first pentavalent meningococcal vaccine approved for protection against serogroups A, B, C, W, and Y. Different manufacturers’ MenB vaccines are not interchangeable; when MenACWY-TT/MenB-FHbp is administered, subsequent doses of MenB should be from the same manufacturer (Pfizer Inc.).